Results 201 to 210 of about 516,619 (288)

Adjuvant Chemotherapy Regimens in Resected Biliary Tract Cancers: National, Comparative, Observational Study (TOG/GI‐SAFRADJU‐2501)

International Journal of Cancer, Volume 159, Issue 11, Page 2766-2777, 1 December 2026.
ABSTRACT The recommended adjuvant chemotherapy (adj‐ChT) regimen for resected biliary tract cancers (BTC) is capecitabine (Cape); yet, the recommendation is based on limited evidence. Although varied adj‐ChTs have been employed in practice, robust real‐world data is scarce. We conducted a national, multicenter, hospital‐based registry study to evaluate
Erman Akkus, Mehmet Kayaalp, Müzeyyen Aslı Ergözoğlu, Ilgın Koç Kuş, Doğan Bayram, Bilgeşah Kılıçtaş, Emel Ayvaz Güneyin, Ali Kalem, Haydar Temizyürek, Mehmet Mutlu Çatlı, Mehmet Sinan Akarca, Maral Martin Mıldanoğlu, Görkem Turhan, Mahmut Kara, Hacı Arak, Feyza Arslan Tan, Burak Paçacı, Berkay Yeşilyurt, Orhun Akdoğan, Emine Bihter Çetin, Selahattin Çelik, Fatma Keskin Uzundere, Elif Şahin, Zehra Sadak Öcal, Lamia Şeker Can, Bahadır Köylü, Mehmet Cem Fidan, Esmanur Kaplan Tüzün, Teoman Şakalar, Elif Sertesen Çamöz, Haydar Çağatay Yüksel, Onur Yazdan Balçık, Pınar Peker, Mehmet Yılmaz, Şeymanur Ala Enli, Erdem Kölemen, Sibel Oyucu Orhan, Yakup Düzköprü, Mustafa Ersoy, Tuğba Akın Telli, Mesut Yılmaz, Yusuf İlhan, Atila Yıldırım, Ramazan Coşar, Müslih Ürün, Arif Hakan Önder, Murat Araz, Ertuğrul Bayram, Havva Yeşil Çınkır, Ali Alkan, Mustafa Gürbüz, Nilüfer Avcı, Fatma Paksoy Türköz, İsmail Oğuz Kara, Fatih Köse, İlkay Tuğba Ünek, Ahmet Bilici, Öznur Bal, Şuayib Yalçın, Lorenza Rimassa, Hatime Arzu Yaşar   +60 more
wiley   +1 more source

Bispecific Antibodies in Solid Tumors: Mechanistic Insights, Clinical Advances, and Future Directions. [PDF]

J Immunother Precis Oncol
Almosa R, Mendoza MM, Tang TY, Stephen B.   +3 more
europepmc   +1 more source

Synergistic Regulation of Biomaterials and Macrophages: A Novel Paradigm in Immunotherapy

MedComm – Biomaterials and Applications, Volume 5, Issue 4, December 2026.
Bioengineered materials mediating the modulation of macrophage plasticity and inflammatory signals in the tumor microenvironment effectively remodel immunoregulatory states, boost antitumor immunity, and promote tissue repair, achieving synergistic therapeutic outcomes.
Jiayu Zhang, Songhang Xing, Shanshan Zhang, Yuan Hao, Xiaojie Qu, Wurihan Bao, Manwei Hao, Han Sun, Mingyuan Dong, Huiling Zhang, Dan Huang, Yiqi Wang, Xuanjie Jiang, Xiaoyu Pu, Yanyan Chi, Xingtong Wang, Xuefeng Li   +16 more
wiley   +1 more source

Evolution and future directions of bispecific antibodies in breast cancer: a global clinical trial landscape analysis. [PDF]

Future Sci OA
Zhu X, Luo S, Li Y.
europepmc   +1 more source

PRAME predicting outcome in uveal melanoma

The Journal of Pathology: Clinical Research, Volume 12, Issue 6, November 2026.
Abstract Uveal melanoma (UM) is the most common primary intra‐ocular malignancy in adults and carries a high risk of metastatic disease, affecting approximately 50% of patients despite advances in local tumour control. PRAME (PReferentially expressed Antigen in MElanoma) has emerged as a marker for metastatic risk; however, evidence is largely derived ...
Sally Owens, Naomi Walsh, Noel Horgan, Patrick Murtagh, Katie Hanratty, Grainne Finegan, Laura Ivers, John Crown, Susan Kennedy   +8 more
wiley   +1 more source

DOTAM-TCB: Universal Small Molecule-guided Hapten- and T Cell-bispecific Antibodies for Cancer Immunotherapy. [PDF]

Antib Ther
Surowka M, Kober T, Matscheko D, Ehler A, Macedo W, Assisi D, Challier J, Sobieniecki A, Gianotti R, Bransi A, Sam J, Bonfiglio JJ, Wichert M, Ricci A, Benz J, Umaña P, Venetz D, Klein C.   +17 more
europepmc   +1 more source

Profiling EGFR, c‐MET, and B7H3 co‐expression to guide next‐generation dual‐drug conjugate strategies in colorectal cancer

The Journal of Pathology: Clinical Research, Volume 12, Issue 6, November 2026.
Abstract Epidermal growth factor receptor (EGFR), cellular mesenchymal‐epithelial transition factor (c‐MET), and B7 homolog 3 (B7H3) are important targets for antibody‐based drug development in colorectal cancer (CRC). To overcome the limitations of single‐target antibody therapies – such as limited efficacy, widespread resistance, narrow patient ...
Yanan Yang, Huiyu Li, Shiwei Xiao, Mengxia Jiao, De Wu, Chunxia Ao, Yanggeling Zhang, Siyuan Yan, Shaomei Sun, Chen Yang, Renhong Tang, Xiyuan Wang, Junqiu Yue   +12 more
wiley   +1 more source

Burden of infections and preventive strategies in patients with relapsed/refractory multiple myeloma treated with bispecific antibodies. [PDF]

Front Oncol
Badelita SN, Murariu DN, Mohorea-Neata AL, Barbu S, Zidaru LE, Cirlan L, Coriu D.   +6 more
europepmc   +1 more source

BCMA Antigen Loss Through Acquired TNFRSF17 Deletion in Multiple Myeloma

International Journal of Laboratory Hematology, EarlyView.
Ali Benaboud, Rémi Tilmont, Gauthier Decool, Nicolas Gower, Salomon Manier, Benjamin Podvin   +5 more
wiley   +1 more source

Navigating Asparaginase Treatment for Patients With Acute Lymphoblastic Leukemia: US Consensus Panel Recommendations on the Role of Multidisciplinary Care

American Journal of Hematology, Volume 101, Issue 11, Page 2713-2725, November 2026.
ABSTRACT Asparaginase is a critical treatment component for patients with acute lymphoblastic leukemia/lymphoblastic lymphoma (ALL/LBL). However, the successful delivery of asparaginase‐based therapy remains challenging across care settings due to its complex administration, distinct toxicity profile, prolonged treatment duration, and the need for ...
Amir Ali, Grace Elsey, Kayla Fulginiti, Zanette Kanani‐Bradley, Holly R. Kubaney, Sandra Kurtin, Theresa Nguyen, Jennifer Turchina, Charlotte B. Wagner   +8 more
wiley   +1 more source